Welcome to our dedicated page for Nevro SEC filings (Ticker: NVRO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings and related regulatory documents for Nevro Corp. (NYSE: NVRO), a global medical device company focused on chronic pain treatment through its 10 kHz spinal cord stimulation (SCS) platform and sacroiliac (SI) joint fusion technologies. While specific filings are not listed in the data provided here, Nevro’s public releases indicate that it regularly files materials with the SEC in connection with its financial reporting and corporate actions.
For a company like Nevro, key SEC filings typically include annual reports on Form 10-K and quarterly reports on Form 10-Q, which describe the business, risk factors, segment performance, research and development spending, and detailed financial statements. Current reports on Form 8-K are used to disclose material events, such as the announced definitive agreement for Globus Medical to acquire all shares of Nevro in an all-cash transaction, as well as significant product, regulatory or financing developments.
In connection with the proposed acquisition, Nevro has stated that it expects to file a proxy statement with the SEC for a special stockholder meeting to obtain shareholder approval. That proxy statement is expected to include information about the transaction terms, background of the merger discussions and potential interests of directors and executive officers in the transaction, along with other required disclosures.
On Stock Titan, Nevro’s SEC filings are paired with AI-powered tools that help interpret lengthy documents. These tools can summarize complex sections of 10-K and 10-Q reports, highlight key changes across periods and surface notable items from current reports. As Nevro continues to report its results and advance the pending acquisition process, this page serves as a central location to review its historical and ongoing SEC disclosure record.
Nevro Corp. was the subject of a Schedule 13G/A filed by Beryl Capital entities and David A. Witkin reporting that none of the reporting persons beneficially own shares of Nevro common stock. The filing lists Beryl Capital Management LLC, Beryl Capital Management LP, Beryl Capital Partners II LP and David A. Witkin as reporting persons, states their organizational relationships, and includes a disclaimer that they do not claim beneficial ownership except for any pecuniary interest. The statement shows 0 shares beneficially owned and 0% of the class, with all voting and dispositive powers reported as zero, indicating no current economic or voting stake disclosed in this filing.
The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC jointly reported beneficial ownership of 1,172 shares of Nevro Corp. common stock, representing 0.0% of the class. The filing shows shared voting power of 905 shares and shared dispositive power of 1,172 shares, with no sole voting or dispositive power recorded.
The Schedule 13G/A states these holdings are reported as held in the ordinary course of business and not for the purpose of influencing control. The filing also discloses that Goldman Sachs & Co. LLC is a subsidiary of The Goldman Sachs Group, Inc., and the parties executed a joint filing agreement documenting the joint submission.
FAQ
What is the current stock price of Nevro (NVRO)?
What is the market cap of Nevro (NVRO)?
